Go Pro
→ Elon's next move will be bigger than the IPO – and it could happen any day now (From Brownstone Research) (Ad)tc pixel Free PRTA Stock Alerts

Prothena (PRTA) Financials

Prothena logo
$8.66 0.00 (0.00%)
Closing price 07/17/2026 04:00 PM Eastern
Extended Trading
$8.60 -0.06 (-0.67%)
As of 07/17/2026 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare
Annual Income Statements for Prothena

Annual Income Statements for Prothena

This table shows Prothena's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Consolidated Net Income / (Loss)		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Net Income / (Loss) Continuing Operations		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Total Pre-Tax Income 		-80 -159 -158 -156 -77 -111 72 -126 -160 -129 -201
Total Operating Income		 -80 -160 -155 -159 -86 -113 72 -132 -191 -155 -215
Total Gross Profit		 1.61 1.06 28 0.96 0.81 0.85 201 54 91 135 9.68
Total Revenue		 1.61 1.06 28 0.96 0.81 0.85 201 54 91 135 9.68
Operating Revenue		 1.61 1.06 28 0.96 0.81 0.85 201 54 91 135 9.68
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 82 161 183 160 87 114 129 185 282 290 224
Selling, General & Admin Expense		 23 41 48 42 36 39 46 50 62 67 59
Research & Development Expense		 58 120 135 101 51 75 82 136 221 223 135
Restructuring Charge		 - 0.00 0.00 16 -0.06 - - - 0.00 0.00 30
Total Other Income / (Expense), net		 0.03 0.57 -2.35 2.74 8.40 1.31 -0.05 5.95 31 26 14
Interest Expense		 -0.20 -0.56 0.14 -2.69 -8.20 -1.37 -0.04 -6.35 -31 -26 -14
Other Income / (Expense), net		 -0.17 0.02 -2.21 0.05 0.20 -0.06 -0.10 -0.40 -0.46 -0.19 -0.33
Income Tax Expense		 0.70 1.14 -4.37 -0.47 0.38 -0.28 4.95 -8.66 -13 -6.62 43
Basic Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.51 ($2.47) ($2.76) ($2.27) ($4.53)
Weighted Average Basic Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 44.23M 47.37M 53.22M 53.77M 53.83M
Diluted Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.38 ($2.47) ($2.76) ($2.27) ($4.53)
Weighted Average Diluted Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 48.46M 47.37M 53.22M 53.77M 53.83M
Weighted Average Basic & Diluted Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 46.69M 52.56M 53.72M 53.83M 53.83M

Quarterly Income Statements for Prothena

This table shows Prothena's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Income / (Loss) Attributable to Common Shareholders		 22 -67 -72 67 -59 -58 -60 -126 -37 -22 33
Consolidated Net Income / (Loss)		 22 -67 -72 67 -59 -58 -60 -126 -37 -22 33
Net Income / (Loss) Continuing Operations		 22 -67 -72 67 -59 -58 -60 -126 -37 -22 33
Total Pre-Tax Income 		19 -71 -74 65 -60 -60 -61 -81 -37 -22 33
Total Operating Income		 10 -79 -82 58 -67 -65 -66 -85 -40 -24 30
Total Gross Profit		 85 0.32 0.05 132 0.97 2.12 2.83 4.42 2.42 0.02 51
Total Revenue		 85 0.32 0.05 132 0.97 2.12 2.83 4.42 2.42 0.02 51
Operating Revenue		 85 0.32 0.05 132 0.97 2.12 2.83 4.42 2.42 0.02 51
Total Cost of Revenue		 0.00 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00
Total Operating Expenses		 75 79 82 74 67 67 68 89 43 24 21
Selling, General & Admin Expense		 17 17 17 16 17 17 18 16 13 13 13
Research & Development Expense		 58 62 64 58 51 50 51 41 29 15 13
Restructuring Charge		 - - - 0.00 0.00 - 0.00 33 0.48 - -4.24
Total Other Income / (Expense), net		 8.51 7.90 7.09 6.47 6.68 5.40 4.21 3.65 3.33 2.62 2.69
Interest Expense		 -8.52 -8.10 -7.17 -6.52 -6.74 -5.39 -4.35 -3.79 -3.35 -2.65 -2.42
Other Income / (Expense), net		 -0.02 -0.21 -0.08 -0.05 -0.07 0.01 -0.14 -0.14 -0.02 -0.02 0.27
Income Tax Expense		 -3.09 -3.14 -2.20 -2.04 -0.84 -1.55 -1.18 45 -0.37 0.01 0.00
Basic Earnings per Share		 $0.41 ($1.25) ($1.34) $1.24 ($1.10) ($1.07) ($1.12) ($2.34) ($0.68) ($0.39) $0.61
Weighted Average Basic Shares Outstanding		 53.56M 53.22M 53.71M 53.77M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 53.71M
Diluted Earnings per Share		 $0.38 ($1.22) ($1.34) $1.22 ($1.10) ($1.05) ($1.12) ($2.34) ($0.68) ($0.39) $0.60
Weighted Average Diluted Shares Outstanding		 58.00M 53.22M 53.71M 55.04M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 54.11M
Weighted Average Basic & Diluted Shares Outstanding		 53.67M 53.72M 53.77M 53.78M 53.81M 53.83M 53.83M 53.83M 53.83M 53.83M 52.35M

Annual Cash Flow Statements for Prothena

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 77 20 31 10 -53 -80 282 132 -92 -149 -164
Net Cash From Operating Activities		 -59 -116 -131 -28 -53 -80 93 -109 -134 -150 -164
Net Cash From Continuing Operating Activities		 -59 -116 -131 -28 -53 -80 93 -109 -134 -150 -164
Net Income / (Loss) Continuing Operations		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Consolidated Net Income / (Loss)		 -81 -160 -153 -156 -78 -111 67 -117 -147 -122 -244
Depreciation Expense		 0.81 2.43 3.07 3.22 1.56 1.51 1.12 0.74 0.93 0.89 0.90
Amortization Expense		 - - 0.00 0.00 5.26 5.46 5.69 6.00 7.48 2.69 2.81
Non-Cash Adjustments To Reconcile Net Income		 11 26 28 31 19 17 19 25 35 44 35
Changes in Operating Assets and Liabilities, net		 11 16 -9.36 93 -0.98 6.89 -0.32 -24 -30 -75 42
Net Cash From Investing Activities		 -1.38 -17 -3.52 -1.73 -0.55 -0.20 -0.58 -0.46 -2.77 -0.30 -0.14
Net Cash From Continuing Investing Activities		 -1.38 -17 -3.52 -1.73 -0.55 -0.20 -0.58 -0.46 -2.77 -0.30 -0.14
Purchase of Property, Plant & Equipment		 -1.38 -17 -3.63 -1.77 -0.56 -0.20 -0.58 -0.46 -2.81 -0.30 -0.14
Sale of Property, Plant & Equipment		 0.00 0.00 0.11 0.04 0.01 - 0.00 0.00 0.04 0.00 0.00
Net Cash From Financing Activities		 137 153 165 40 0.23 0.22 190 241 45 1.55 -0.14
Net Cash From Continuing Financing Activities		 137 153 165 40 0.23 0.22 190 241 45 1.55 -0.14
Issuance of Common Equity		 131 129 150 40 0.00 0.00 78 173 21 0.00 0.00
Other Financing Activities, net		 5.65 25 15 0.29 0.23 0.22 112 69 24 1.55 -0.14
Cash Income Taxes Paid		 0.44 0.58 0.29 -1.00 1.58 1.37 0.58 2.66 1.55 3.17 0.93

Quarterly Cash Flow Statements for Prothena

This table details how cash moves in and out of Prothena's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
Net Change in Cash & Equivalents		 12 -52 -72 16 -45 -48 -53 -47 -41 -23 22
Net Cash From Operating Activities		 9.52 -51 -73 16 -45 -48 -53 -46 -41 -23 29
Net Cash From Continuing Operating Activities		 9.52 -51 -74 16 -45 -48 -53 -46 -41 -23 29
Net Income / (Loss) Continuing Operations		 22 -67 -72 67 -59 -58 -60 -126 -37 -22 33
Consolidated Net Income / (Loss)		 22 -67 -72 67 -59 -58 -60 -126 -37 -22 33
Depreciation Expense		 0.23 0.28 0.22 0.23 0.23 0.22 0.22 0.23 0.23 0.22 0.18
Non-Cash Adjustments To Reconcile Net Income		 9.33 9.55 12 11 10 9.87 10 13 5.93 4.38 1.73
Changes in Operating Assets and Liabilities, net		 -24 4.35 -14 -63 2.53 -0.60 -4.38 66 -10 -9.13 -5.76
Net Cash From Investing Activities		 -0.44 -1.51 -0.10 -0.14 -0.01 -0.04 -0.04 -0.09 -0.01 - 0.00
Net Cash From Continuing Investing Activities		 -0.44 -1.51 -0.10 -0.14 -0.01 -0.04 -0.04 -0.09 -0.01 - 0.00
Purchase of Property, Plant & Equipment		 -0.44 -1.55 -0.10 -0.14 -0.01 -0.04 -0.04 -0.09 -0.01 - 0.00
Sale of Property, Plant & Equipment		 - - - - - - 0.00 - - - 0.00
Net Cash From Financing Activities		 2.71 0.48 0.84 0.44 0.33 -0.06 -0.05 -0.07 -0.02 - -6.95
Net Cash From Continuing Financing Activities		 2.71 0.48 0.89 0.39 0.33 -0.06 -0.05 -0.07 -0.02 - -6.95
Repurchase of Common Equity		 - - - - - - - - - - -6.95
Issuance of Common Equity		 - - - - - - 0.00 -0.07 -0.02 0.14 0.00
Cash Income Taxes Paid		 0.05 1.17 0.02 1.56 0.84 0.76 0.00 0.94 0.00 -0.01 0.00

Annual Balance Sheets for Prothena

This table presents Prothena's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 385 460 496 499 419 333 609 758 696 547 327
Total Current Assets		 377 391 426 431 378 299 585 719 639 485 315
Cash & Equivalents		 371 387 418 428 376 295 579 710 619 471 308
Prepaid Expenses		 6.31 4.26 8.47 3.73 2.58 2.54 5.72 8.69 14 14 7.66
Plant, Property, & Equipment, net		 3.86 56 55 53 3.87 2.55 2.01 1.73 3.84 3.08 2.14
Total Noncurrent Assets		 3.97 12 15 15 37 31 23 37 53 59 9.47
Other Noncurrent Operating Assets		 1.12 2.19 6.90 4.87 27 19 15 19 19 15 9.47
Total Liabilities & Shareholders' Equity		 385 460 496 499 419 333 609 758 696 547 327
Total Liabilities		 25 95 89 176 146 149 143 136 135 60 46
Total Current Liabilities		 22 41 37 15 18 26 33 50 57 49 41
Accounts Payable		 4.52 13 14 1.47 1.24 4.12 3.69 9.27 25 7.77 5.88
Accrued Expenses		 13 19 14 5.37 5.83 9.04 6.35 11 15 13 4.33
Current Deferred Revenue		 - - - - - 0.00 7.66 11 0.00 8.85 2.66
Other Current Liabilities		 4.90 8.56 9.92 8.03 11 13 16 19 17 18 28
Total Noncurrent Liabilities		 2.35 53 52 161 129 123 110 86 78 12 5.49
Other Noncurrent Operating Liabilities		 0.13 - 0.00 0.55 18 13 6.94 0.55 11 8.23 5.49
Commitments & Contingencies		 - - - - - - 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 361 365 407 323 273 184 466 622 561 487 280
Total Preferred & Common Equity		 361 365 407 323 273 184 466 622 561 487 280
Total Common Equity		 361 365 407 323 273 184 466 622 561 487 280
Common Stock		 490 655 850 921 945 967 1,182 1,455 1,541 1,589 1,627
Retained Earnings		 -129 -289 -442 -598 -672 -783 -716 -833 -980 -1,102 -1,346
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Quarterly Balance Sheets for Prothena

This table presents Prothena's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026
Total Assets		 554 742 721 747 623 646 595 495 399 353 350
Total Current Assets		 525 700 677 691 566 586 535 436 385 340 339
Cash & Equivalents		 496 686 659 671 547 564 519 418 371 331 329
Prepaid Expenses		 29 14 16 13 18 22 16 18 14 9.13 9.74
Plant, Property, & Equipment, net		 2.00 1.92 2.17 2.43 3.67 3.49 3.25 2.87 2.69 2.46 1.96
Total Noncurrent Assets		 28 39 41 54 54 56 57 56 11 10 8.73
Other Noncurrent Operating Assets		 13 18 15 24 17 17 16 11 11 10 8.73
Total Liabilities & Shareholders' Equity		 554 742 721 747 623 646 595 495 399 353 350
Total Liabilities		 150 134 139 130 121 64 61 58 75 58 37
Total Current Liabilities		 51 49 72 53 43 47 46 48 68 51 33
Accounts Payable		 9.79 13 14 19 14 9.29 10 16 12 11 4.30
Accrued Expenses		 12 14 19 18 17 16 10 13 11 9.54 4.61
Current Deferred Revenue		 9.67 9.32 25 0.32 0.00 8.03 8.83 7.90 5.10 2.69 1.63
Other Current Liabilities		 20 13 14 16 12 14 17 12 40 29 22
Total Noncurrent Liabilities		 99 85 67 76 78 17 14 9.20 6.93 6.20 4.76
Other Noncurrent Operating Liabilities		 2.20 0.00 0.00 8.92 10 9.54 8.88 7.58 6.93 6.20 4.76
Commitments & Contingencies		 - 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 405 607 582 617 502 582 534 438 324 295 313
Total Preferred & Common Equity		 405 607 582 617 502 582 534 438 324 295 313
Total Common Equity		 405 607 582 617 502 582 534 438 324 295 313
Common Stock		 1,244 1,487 1,516 1,530 1,555 1,567 1,579 1,600 1,613 1,620 1,626
Retained Earnings		 -839 -880 -934 -913 -1,052 -985 -1,044 -1,163 -1,288 -1,325 -1,314
Other Equity Adjustments		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00

Annual Metrics And Ratios for Prothena

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
DEI Shares Outstanding		 31,522,750.00 34,488,428.00 38,446,761.00 39,863,711.00 39,896,561.00 39,921,413.00 46,593,782.00 - - - 53,829,982.00
DEI Adjusted Shares Outstanding		 31,522,750.00 34,488,428.00 38,446,761.00 39,863,711.00 39,896,561.00 39,921,413.00 46,593,782.00 - - - 53,829,982.00
DEI Earnings Per Adjusted Shares Outstanding		 -2.56 -4.64 -3.99 -3.90 -1.95 -2.78 1.44 - - - -4.53
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 -96.84% -34.35% 2,508.44% -96.53% -14.76% 4.79% 23,414.30% -73.13% 69.50% 47.92% -92.84%
EBITDA Growth		 -1,297.37% -98.10% 1.72% -0.78% 49.43% -34.49% 174.36% -259.14% -46.22% 17.44% -39.76%
EBIT Growth		 -1,148.16% -99.13% 1.29% -0.85% 46.16% -31.92% 163.72% -283.58% -45.12% 19.19% -38.92%
NOPAT Growth		 -1,102.24% -99.58% 2.68% -2.32% 46.05% -31.55% 184.93% -237.40% -45.21% 19.09% -38.87%
Net Income Growth		 -1,027.44% -98.62% 4.29% -1.57% 50.09% -43.08% 160.26% -274.62% -25.72% 16.81% -99.57%
EPS Growth		 -817.24% -75.19% 12.66% 3.44% 50.38% -42.56% 149.64% -278.99% -11.74% 17.75% -99.56%
Operating Cash Flow Growth		 -8,479.80% -98.38% -12.85% 78.45% -87.33% -51.72% 215.23% -217.51% -23.05% -12.06% -9.02%
Free Cash Flow Firm Growth		 -1,037.62% -196.28% 15.83% 36.47% 165.35% -233.99% 197.63% -273.39% -39.81% -11.81% 41.03%
Invested Capital Growth		 -168.75% 359.59% 59.59% -78.88% -1,284.90% -9.65% -0.29% 21.84% 33.44% 126.42% -274.13%
Revenue Q/Q Growth		 -51.49% -11.42% 0.21% -3.54% 8.24% 13.89% 0.41% 945.89% -35.19% 1.36% -17.83%
EBITDA Q/Q Growth		 -16.44% -17.83% 0.65% 13.76% 0.55% -7.20% -3.44% 20.73% -73.42% 7.47% 17.06%
EBIT Q/Q Growth		 -16.29% -18.12% 0.72% 13.50% -0.56% -6.74% -3.67% 19.86% -69.20% 8.21% 15.91%
NOPAT Q/Q Growth		 -16.14% -18.64% 1.25% 13.39% -0.61% -6.65% -3.61% 20.06% -69.67% 8.10% 15.94%
Net Income Q/Q Growth		 -15.88% -18.28% 0.74% 13.98% 1.15% -8.98% -3.55% 25.26% -100.85% 7.22% 12.97%
EPS Q/Q Growth		 -5.56% -15.35% 3.78% 15.12% 0.51% -8.59% 32.69% 19.02% -100.00% 6.97% 12.72%
Operating Cash Flow Q/Q Growth		 -5.97% -18.30% -4.56% 39.25% 11.32% -6.08% -3.51% 13.84% -52.44% 2.13% 13.01%
Free Cash Flow Firm Q/Q Growth		 -15.85% -11.78% -3.12% -218.05% 313.87% -0.34% -7.48% 12.76% -42.26% 2.82% 15.75%
Invested Capital Q/Q Growth		 -0.69% -7.49% 8.00% 113.23% -1.65% -5.98% -3.12% 2.88% -6.90% 2.90% 24.54%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -4,934.72% -14,890.33% -561.05% -16,292.25% -9,665.97% -12,405.51% 39.23% -232.28% -200.37% -111.84% -2,181.60%
Operating Margin		 -4,974.30% -15,121.80% -564.17% -16,634.03% -10,527.89% -13,216.18% 35.88% -244.05% -209.08% -114.36% -2,216.44%
EBIT Margin		 -4,984.88% -15,120.38% -572.19% -16,629.01% -10,503.81% -13,223.45% 35.84% -244.79% -209.58% -114.49% -2,219.83%
Profit (Net Income) Margin		 -5,016.30% -15,176.11% -556.84% -16,297.91% -9,542.63% -13,029.78% 33.39% -216.95% -160.92% -90.49% -2,520.57%
Tax Burden Percent		 100.88% 100.72% 97.23% 99.70% 100.49% 99.75% 93.12% 93.11% 91.62% 94.87% 121.54%
Interest Burden Percent		 99.76% 99.65% 100.09% 98.30% 90.41% 98.79% 100.06% 95.19% 83.80% 83.32% 93.42%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 6.88% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% -1,411.19% -325.25% -446.94% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% -1,397.55% -312.62% -484.48% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 1,367.09% 285.58% 613.39% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 -24.78% -44.10% -39.67% 166.45% 48.35% -48.65% 20.61% -21.50% -24.85% -23.34% -63.62%
Cash Return on Invested Capital (CROIC)		 0.00% -572.31% -371.16% -316.68% 0.00% 0.00% 0.00% 0.00% 0.00% -1,174.85% 0.00%
Operating Return on Assets (OROA)		 -23.24% -37.75% -32.93% -58.98% -37.06% -29.99% 15.26% -19.30% -26.33% -24.89% -49.20%
Return on Assets (ROA)		 -23.39% -37.89% -32.05% -57.80% -33.66% -29.55% 14.21% -17.11% -20.22% -19.67% -55.86%
Return on Common Equity (ROCE)		 -24.78% -44.10% -39.67% 166.45% 48.35% -48.65% 20.61% -21.50% -24.85% -23.34% -63.62%
Return on Equity Simple (ROE_SIMPLE)		 -22.35% -43.82% -37.63% 26.19% -28.46% -60.40% 14.37% -18.80% -26.19% -25.12% 0.00%
Net Operating Profit after Tax (NOPAT)		 -56 -112 -109 -111 -60 -79 67 -92 -134 -108 -150
NOPAT Margin		 -3,482.01% -10,585.26% -394.92% -11,643.82% -7,369.52% -9,251.32% 33.42% -170.84% -146.36% -80.05% -1,551.51%
Net Nonoperating Expense Percent (NNEP)		 -7.42% -13.64% -12.63% 37.54% 15.57% -9.59% -0.01% -3.86% -2.00% -2.59% -24.10%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -14.80% -23.82% -22.22% -53.57%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 1,437.77% 3,891.56% 175.25% 4,448.38% 4,390.17% 4,537.28% 23.09% 92.57% 67.68% 49.72% 613.30%
R&D to Revenue		 3,636.53% 11,330.24% 488.92% 10,595.08% 6,245.21% 8,778.90% 41.02% 251.48% 241.40% 164.64% 1,392.52%
Operating Expenses to Revenue		 5,074.30% 15,221.80% 664.17% 16,734.03% 10,627.89% 13,316.18% 64.12% 344.05% 309.08% 214.36% 2,316.44%
Earnings before Interest and Taxes (EBIT)		 -80 -160 -157 -159 -86 -113 72 -132 -191 -155 -215
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -79 -157 -154 -156 -79 -106 79 -125 -183 -151 -211
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.95 4.64 3.54 0.00 2.31 2.61 4.94 4.69 3.47 1.53 1.83
Price to Tangible Book Value (P/TBV)		 5.95 4.64 3.54 0.00 2.31 2.61 4.94 4.69 3.47 1.53 1.83
Price to Revenue (P/Rev)		 1,336.04 1,608.04 52.38 429.94 775.88 562.08 11.48 54.07 21.34 5.51 53.09
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 34.37 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2.91% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 52.86 26.17 47.33 0.00 0.00 0.00 0.00 0.00 17.63 0.00
Enterprise Value to Revenue (EV/Rev)		 1,105.43 1,289.94 39.07 429.94 314.30 214.21 8.59 40.89 14.56 2.03 21.33
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 21.89 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 23.97 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 25.70 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 18.60 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 4.97 0.00 25.58 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.14 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.14 0.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.02 -0.98 -0.91 -1.27 -0.71 -1.47 -1.35 -1.19 -1.12 -1.04 -1.02
Leverage Ratio		 1.06 1.16 1.24 -2.88 -1.44 1.65 1.45 1.26 1.23 1.19 1.14
Compound Leverage Factor		 1.06 1.16 1.24 -2.83 -1.30 1.63 1.45 1.20 1.03 0.99 1.06
Debt to Total Capital		 0.00% 12.32% 11.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 12.32% 11.23% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 87.68% 88.77% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 -0.33 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 2.14 2.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 -0.33 -0.33 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 -0.46 -0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 3.01 3.37 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 -0.46 -0.47 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 52.39 9.65 8.40 -25.05 0.71 -1.49 9.79 11.88 6.92 4.88 -0.24
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 16.99 9.53 11.41 0.00 21.36 11.58 17.48 14.34 11.24 10.01 7.72
Quick Ratio		 16.70 9.42 11.18 0.00 21.21 11.43 17.31 14.17 10.97 9.72 7.53
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -50 -147 -124 -79 51 -69 67 -117 -163 -183 -108
Operating Cash Flow to CapEx		 -4,240.23% -698.45% -3,725.73% -1,635.40% -9,683.55% -41,001.02% 16,105.22% -23,452.80% -4,828.92% -50,352.35% -118,536.23%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 -873.36 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 -923.82 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 -948.62 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.06 0.00 0.00 0.00 0.43 0.08 0.13 0.22 0.02
Accounts Receivable Turnover		 1.42 3.07 131.67 0.00 0.00 20.55 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.46 0.04 0.49 0.03 0.18 0.27 87.91 28.80 32.83 39.08 3.71
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 257.57 118.84 2.77 0.00 0.00 17.76 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 257.57 118.84 2.77 0.00 0.00 17.76 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -9.92 26 41 8.68 -103 -113 -113 -88 -59 16 -27
Invested Capital Turnover		 -0.24 0.13 0.82 0.04 -0.02 -0.01 -1.78 -0.54 -1.24 -6.25 -1.68
Increase / (Decrease) in Invested Capital		 -6.23 36 15 -32 -111 -9.92 -0.33 25 30 74 -43
Enterprise Value (EV)		 1,776 1,361 1,075 411 256 183 1,723 2,204 1,330 274 207
Market Capitalization		 2,147 1,696 1,441 411 632 479 2,302 2,915 1,950 745 514
Book Value per Share		 $11.44 $10.59 $10.59 ($14.91) $6.84 $4.61 $10.00 $12.86 $10.46 $9.05 $5.21
Tangible Book Value per Share		 $11.44 $10.59 $10.59 ($14.91) $6.84 $4.61 $10.00 $12.86 $10.46 $9.05 $5.21
Total Capital		 361 417 459 -594 273 184 466 622 561 487 280
Total Debt		 0.00 51 52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 51 52 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -371 -336 -366 0.00 -376 -297 -579 -710 -620 -471 -308
Capital Expenditures (CapEx)		 1.38 17 3.52 1.73 0.55 0.20 0.58 0.46 2.77 0.30 0.14
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -15 -37 -29 -11 -15 -23 -28 -41 -38 -34 -33
Debt-free Net Working Capital (DFNWC)		 355 350 389 -11 361 273 551 669 582 437 274
Net Working Capital (NWC)		 355 350 389 -11 361 273 551 669 582 437 274
Net Nonoperating Expense (NNE)		 25 48 45 44 18 32 0.05 25 13 14 94
Net Nonoperating Obligations (NNO)		 -371 -340 -366 603 -376 -297 -579 -710 -620 -471 -308
Total Depreciation and Amortization (D&A)		 0.81 2.43 3.07 3.22 6.82 6.98 6.80 6.74 8.41 3.59 3.70
Debt-free, Cash-free Net Working Capital to Revenue		 -958.25% -3,472.61% -104.16% -1,109.84% -1,850.37% -2,731.07% -13.83% -76.90% -41.36% -25.51% -342.64%
Debt-free Net Working Capital to Revenue		 22,102.49% 33,202.56% 1,413.41% -1,109.84% 44,307.25% 32,055.80% 274.89% 1,240.98% 637.40% 323.26% 2,833.02%
Net Working Capital to Revenue		 22,102.49% 33,202.56% 1,413.41% -1,109.84% 44,307.25% 32,055.80% 274.89% 1,240.98% 637.40% 323.26% 2,833.02%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.51 ($2.47) ($2.76) ($2.27) ($4.53)
Adjusted Weighted Average Basic Shares Outstanding		 34.34M 35.03M 38.54M 39.86M 39.91M 39.99M 44.23M 47.37M 53.22M 53.77M 53.83M
Adjusted Diluted Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $1.38 ($2.47) ($2.76) ($2.27) ($4.53)
Adjusted Weighted Average Diluted Shares Outstanding		 34.34M 35.03M 38.54M 39.86M 39.91M 39.99M 48.46M 47.37M 53.22M 53.77M 53.83M
Adjusted Basic & Diluted Earnings per Share		 ($2.66) ($4.66) ($4.07) ($3.93) ($1.95) ($2.78) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 30.33M 34.35M 37.65M 39.56M 39.88M 39.92M 46.69M 52.56M 53.72M 53.83M 53.83M
Normalized Net Operating Profit after Tax (NOPAT)		 -56 -112 -109 -100 -60 -79 67 -92 -134 -108 -129
Normalized NOPAT Margin		 -3,482.01% -10,585.26% -394.92% -10,460.42% -7,374.77% -9,251.32% 33.42% -170.84% -146.36% -80.05% -1,334.08%
Pre Tax Income Margin		 -4,972.68% -15,067.68% -572.71% -16,347.12% -9,496.07% -13,062.95% 35.86% -233.01% -175.64% -95.39% -2,073.82%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 -1,108.88 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 -765.34 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 -1,133.68 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 -790.13 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Prothena

This table displays calculated financial ratios and metrics derived from Prothena's official financial filings.

Metric Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026
Period end date 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026
DEI Shares Outstanding		 - - - - - - 53,826,982.00 53,826,982.00 53,829,982.00 53,829,982.00 53,832,982.00
DEI Adjusted Shares Outstanding		 - - - - - - 53,826,982.00 53,826,982.00 53,829,982.00 53,829,982.00 53,832,982.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - -1.12 -2.34 -0.68 -0.40 0.61
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 5,494.33% -99.37% -97.69% 3,184.75% -98.86% 571.84% 5,556.00% -96.65% 148.97% -99.01% 1,706.36%
EBITDA Growth		 125.93% -5,836.52% -48.77% 190.37% -621.08% 16.02% 20.37% -244.36% 39.67% 62.88% 147.04%
EBIT Growth		 120.45% -19,629.32% -44.52% 187.58% -746.84% 17.57% 19.46% -245.32% 39.53% 62.67% 146.11%
NOPAT Growth		 134.07% -40,116.93% -44.75% 229.34% -487.93% 17.34% 19.56% -198.37% 39.50% 62.71% 165.42%
Net Income Growth		 147.87% -1,162.78% -54.15% 222.51% -369.32% 14.11% 16.67% -288.03% 38.07% 62.75% 154.36%
EPS Growth		 139.18% -862.50% -50.56% 218.45% -389.47% 13.93% 16.42% -291.80% 38.18% 62.86% 153.57%
Operating Cash Flow Growth		 130.54% -925.68% -53.93% 135.52% -574.79% 6.40% 26.95% -390.37% 10.23% 51.20% 154.11%
Free Cash Flow Firm Growth		 55.54% -240.42% -39.56% 47.50% -387.06% -41.74% -22.94% 115.58% 119.53% 121.42% 159.96%
Invested Capital Growth		 39.52% 33.44% 42.29% 122.58% 127.44% 126.42% 143.43% -364.73% -337.44% -274.13% -185.32%
Revenue Q/Q Growth		 2,011.62% -99.63% -84.18% 263,928.00% -99.27% 118.87% 33.21% 56.29% -45.36% -99.13% 243,157.14%
EBITDA Q/Q Growth		 119.45% -704.32% -6.84% 171.95% -212.18% 2.61% -0.22% -29.06% 52.64% 40.03% 227.00%
EBIT Q/Q Growth		 115.45% -864.79% -3.66% 171.47% -214.15% 2.54% -1.28% -28.97% 52.50% 39.83% 225.10%
NOPAT Q/Q Growth		 125.78% -557.93% -3.84% 205.51% -177.32% 2.43% -1.05% -29.03% 52.44% 39.85% 277.27%
Net Income Q/Q Growth		 140.13% -408.01% -7.06% 192.59% -188.21% 1.77% -3.86% -108.93% 70.95% 40.92% 251.56%
EPS Q/Q Growth		 136.89% -421.05% -9.84% 191.04% -190.16% 4.55% -6.67% -108.93% 70.94% 42.65% 253.85%
Operating Cash Flow Q/Q Growth		 121.18% -636.28% -43.13% 121.85% -383.14% -5.72% -11.70% 13.16% 12.46% 42.53% 223.87%
Free Cash Flow Firm Q/Q Growth		 65.41% -252.76% -6.95% 59.76% -220.87% -2.66% 7.23% 105.10% 302.17% 12.58% 159.72%
Invested Capital Q/Q Growth		 30.16% -6.90% 22.70% 139.14% -15.14% 2.90% 27.08% -338.56% 23.88% 24.54% 37.74%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 14.85% -24,107.91% -162,780.00% 44.36% -6,771.86% -3,013.42% -2,291.80% -1,912.53% -1,657.72% -114,319.05% 59.69%
Operating Margin		 12.15% -24,846.52% -163,056.00% 44.22% -6,857.01% -3,056.85% -2,318.99% -1,914.39% -1,666.25% -115,252.38% 58.80%
EBIT Margin		 12.13% -24,911.39% -163,210.00% 44.18% -6,863.81% -3,056.43% -2,323.94% -1,917.62% -1,667.21% -115,357.14% 59.33%
Profit (Net Income) Margin		 25.81% -21,353.16% -144,478.00% 50.67% -6,082.58% -2,729.91% -2,128.54% -2,845.41% -1,513.08% -102,804.76% 64.05%
Tax Burden Percent		 116.43% 95.55% 97.04% 103.14% 98.60% 97.40% 98.08% 155.34% 98.99% 100.05% 100.00%
Interest Burden Percent		 182.79% 89.71% 91.22% 111.18% 89.87% 91.70% 93.38% 95.52% 91.68% 89.08% 107.97%
Effective Tax Rate		 -16.43% 0.00% 0.00% -3.14% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,350.12%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 2,349.40%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -2,340.32%
Return on Equity (ROE)		 -14.33% -24.85% -31.07% -8.75% -22.90% -23.34% -23.46% -66.85% -67.63% -63.62% 9.80%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% -902.20% -1,244.02% -1,174.85% -821.68% 0.00% 0.00% 0.00% 0.00%
Operating Return on Assets (OROA)		 2.63% -3,129.99% -21,346.53% 14.05% -1,363.89% -664.42% -573.17% -37.97% -41.46% -2,556.59% 8.13%
Return on Assets (ROA)		 5.59% -2,682.92% -18,896.53% 16.11% -1,208.65% -593.44% -524.97% -56.33% -37.63% -2,278.40% 8.78%
Return on Common Equity (ROCE)		 -14.33% -24.85% -31.07% -8.75% -22.90% -23.34% -23.46% -66.85% -67.63% -63.62% 9.80%
Return on Equity Simple (ROE_SIMPLE)		 -11.86% 0.00% -34.32% -8.75% -24.67% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 12 -55 -57 60 -47 -45 -46 -59 -28 -17 30
NOPAT Margin		 14.14% -17,392.56% -114,139.20% 45.61% -4,799.91% -2,139.80% -1,623.29% -1,340.07% -1,166.38% -80,676.67% 58.79%
Net Nonoperating Expense Percent (NNEP)		 1.70% -1.88% -2.46% 1.09% -2.09% -2.30% -2.96% -14.22% -1.97% -1.19% 0.72%
Return On Investment Capital (ROIC_SIMPLE)		 - -9.79% - - - -9.33% -10.49% -18.26% -9.55% -6.04% 9.61%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 19.61% 5,360.76% 34,928.00% 12.22% 1,727.84% 793.59% 622.28% 359.95% 548.16% 60,219.05% 24.79%
R&D to Revenue		 68.24% 19,585.76% 128,228.00% 43.56% 5,229.18% 2,363.26% 1,796.71% 916.67% 1,198.26% 69,457.14% 24.72%
Operating Expenses to Revenue		 87.85% 24,946.52% 163,156.00% 55.78% 6,957.01% 3,156.85% 2,418.99% 2,014.39% 1,766.25% 115,352.38% 41.20%
Earnings before Interest and Taxes (EBIT)		 10 -79 -82 58 -67 -65 -66 -85 -40 -24 30
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 13 -76 -81 59 -66 -64 -65 -85 -40 -24 30
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.19 3.47 2.65 1.91 1.68 1.53 1.52 1.01 1.78 1.83 1.67
Price to Tangible Book Value (P/TBV)		 4.19 3.47 2.65 1.91 1.68 1.53 1.52 1.01 1.78 1.83 1.67
Price to Revenue (P/Rev)		 18.32 21.34 14.89 5.11 6.75 5.51 4.83 31.60 44.58 53.09 9.03
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 0.00 30.67 25.20 17.63 12.57 0.00 0.00 0.00 0.00
Enterprise Value to Revenue (EV/Rev)		 13.55 14.56 8.76 2.51 2.85 2.03 1.80 0.00 16.51 21.33 3.34
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -1.14 -1.12 -1.11 -1.05 -1.03 -1.04 -1.03 -1.03 -1.03 -1.02 -1.00
Leverage Ratio		 1.27 1.23 1.23 1.17 1.17 1.19 1.19 1.15 1.14 1.14 1.13
Compound Leverage Factor		 2.33 1.10 1.12 1.31 1.05 1.09 1.11 1.10 1.05 1.01 1.22
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 11.50 7.46 4.96 9.96 7.25 5.42 4.43 -1.62 0.85 1.68 4.67
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 12.94 11.24 13.08 12.54 11.52 10.01 9.00 5.68 6.61 7.72 10.43
Quick Ratio		 12.67 10.97 12.63 12.07 11.19 9.72 8.62 5.48 6.43 7.53 10.13
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -24 -85 -90 -36 -117 -120 -111 5.67 23 26 67
Operating Cash Flow to CapEx		 2,153.17% -3,294.90% -70,923.30% 11,160.14% -502,066.67% -111,097.67% -127,054.76% -53,883.72% -405,650.00% 0.00% 0.00%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.22 0.13 0.13 0.32 0.20 0.22 0.25 0.02 0.02 0.02 0.14
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 63.65 32.83 31.90 76.82 46.90 39.08 42.16 3.35 4.12 3.71 23.99
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 -55 -59 -45 18 15 16 20 -47 -36 -27 -17
Invested Capital Turnover		 -1.93 -1.24 -1.44 -7.12 -6.68 -6.25 -10.73 -0.71 -1.14 -1.68 39.97
Increase / (Decrease) in Invested Capital		 36 30 33 97 70 74 65 -65 -51 -43 -37
Enterprise Value (EV)		 1,911 1,330 781 546 380 274 248 -45 195 207 194
Market Capitalization		 2,583 1,950 1,329 1,110 900 745 666 327 525 514 523
Book Value per Share		 $11.53 $10.46 $9.35 $10.82 $9.94 $9.05 $8.13 $6.03 $5.48 $5.21 $5.81
Tangible Book Value per Share		 $11.53 $10.46 $9.35 $10.82 $9.94 $9.05 $8.13 $6.03 $5.48 $5.21 $5.81
Total Capital		 617 561 502 582 534 487 438 324 295 280 313
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -672 -620 -548 -564 -519 -471 -418 -371 -331 -308 -329
Capital Expenditures (CapEx)		 0.44 1.55 0.10 0.14 0.01 0.04 0.04 0.09 0.01 0.00 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -35 -38 -25 -25 -31 -34 -30 -54 -42 -33 -23
Debt-free Net Working Capital (DFNWC)		 637 582 523 539 489 437 388 318 289 274 307
Net Working Capital (NWC)		 637 582 523 539 489 437 388 318 289 274 307
Net Nonoperating Expense (NNE)		 -9.91 13 15 -6.67 12 13 14 67 8.37 4.65 -2.69
Net Nonoperating Obligations (NNO)		 -672 -620 -548 -564 -519 -471 -418 -371 -331 -308 -329
Total Depreciation and Amortization (D&A)		 2.31 2.54 0.22 0.23 0.89 0.91 0.91 0.23 0.23 0.22 0.18
Debt-free, Cash-free Net Working Capital to Revenue		 -24.84% -41.36% -28.30% -11.46% -23.02% -25.51% -21.91% -519.94% -358.94% -342.64% -39.31%
Debt-free Net Working Capital to Revenue		 452.01% 637.40% 585.54% 248.21% 366.38% 323.26% 281.08% 3,071.93% 2,448.14% 2,833.02% 529.31%
Net Working Capital to Revenue		 452.01% 637.40% 585.54% 248.21% 366.38% 323.26% 281.08% 3,071.93% 2,448.14% 2,833.02% 529.31%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 $0.41 ($1.25) ($1.34) $1.24 ($1.10) ($1.07) ($1.12) ($2.34) ($0.68) ($0.39) $0.61
Adjusted Weighted Average Basic Shares Outstanding		 53.56M 53.22M 53.71M 53.77M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 53.71M
Adjusted Diluted Earnings per Share		 $0.38 ($1.22) ($1.34) $1.22 ($1.10) ($1.05) ($1.12) ($2.34) ($0.68) ($0.39) $0.60
Adjusted Weighted Average Diluted Shares Outstanding		 58.00M 53.22M 53.71M 55.04M 53.79M 53.77M 53.83M 53.83M 53.83M 53.83M 54.11M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 53.67M 53.72M 53.77M 53.78M 53.81M 53.83M 53.83M 53.83M 53.83M 53.83M 52.35M
Normalized Net Operating Profit after Tax (NOPAT)		 7.22 -55 -57 41 -47 -45 -46 -36 -28 -17 26
Normalized NOPAT Margin		 8.50% -17,392.56% -114,139.20% 30.95% -4,799.91% -2,139.80% -1,623.29% -823.64% -1,152.49% -80,676.67% 50.49%
Pre Tax Income Margin		 22.17% -22,347.47% -148,880.00% 49.12% -6,168.66% -2,802.68% -2,170.19% -1,831.79% -1,528.45% -102,757.14% 64.06%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Prothena’s latest quarter shows a business that is back in strong revenue and earnings mode after a very weak second half of 2024. In Q1 2026, revenue jumped to $51.1 million versus just $21,000 in Q4 2025 and $2.4 million in Q3 2025, while net income improved to $32.7 million from a $21.6 million loss in the prior quarter. That’s a meaningful turnaround for a company that remains heavily tied to biotech milestone and collaboration-type revenue.

On the cash side, Prothena remains well capitalized. It ended Q1 2026 with $329.5 million in cash and equivalents and $312.6 million in total equity, against only $37.3 million in liabilities. That gives the company a very healthy balance sheet cushion even after a volatile stretch in operations and cash usage.

The main caution is that the business is still not consistently profitable across a full cycle. Operating expenses remain substantial, and results have been highly variable quarter to quarter. Revenue has swung dramatically, and cash flow has also been uneven, so investors should not treat the latest profit as proof of a stable earnings model yet.

  • Revenue rebounded sharply in Q1 2026 to $51.1 million from near-zero levels in Q4 2025, showing a strong operational reset.
  • Net income turned positive at $32.7 million, a major improvement from losses in the prior quarter and the year-ago period.
  • Operating cash flow was solid at $28.9 million in Q1 2026, supporting the earnings rebound.
  • Cash balance remains large at $329.5 million, giving the company runway to fund R&D and operations.
  • Balance sheet leverage is low, with liabilities of just $37.3 million versus $312.6 million in equity.
  • Q1 2026 gross margin appears very high because cost of revenue was reported as zero, likely reflecting the nature of the revenue mix rather than a traditional product business.
  • R&D spending remains meaningful at $12.6 million, which is typical for a clinical-stage biotech but keeps profitability dependent on revenue events.
  • Recent quarters have been volatile, with swings from a $125.8 million loss in Q2 2025 to a $32.7 million profit in Q1 2026.
  • Profitability is not yet consistent; the company posted large losses in most of the last four years outside of a few strong quarters.
  • Revenue has been highly lumpy, suggesting heavy dependence on milestone timing or collaboration receipts rather than recurring sales.

Looking at the last four years, the pattern is clear: Prothena has moved from very large cash reserves and irregular revenue toward a smaller but still strong cash position, while the income statement remains highly dependent on non-recurring items and development spending. The company’s financial risk is much lower than it would be for a cash-strapped biotech, but investors should still expect volatility in both revenue and earnings.

07/20/26 02:35 AM ETAI Generated. May Contain Errors.

Prothena Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Prothena's fiscal year ends in December. Their fiscal year 2025 ended on December 31, 2025.

Prothena's net income appears to be on an upward trend, with a most recent value of -$244.09 million in 2025, rising from -$80.61 million in 2015. The previous period was -$122.31 million in 2024. Find out what analysts predict for Prothena in the coming months.

Prothena's total operating income in 2025 was -$214.64 million, based on the following breakdown:
  • Total Gross Profit: $9.68 million
  • Total Operating Expenses: $224.32 million

Over the last 10 years, Prothena's total revenue changed from $1.61 million in 2015 to $9.68 million in 2025, a change of 502.6%.

Prothena's total liabilities were at $46.33 million at the end of 2025, a 23.0% decrease from 2024, and a 88.6% increase since 2015.

In the past 10 years, Prothena's cash and equivalents has ranged from $295.38 million in 2020 to $710.41 million in 2022, and is currently $307.53 million as of their latest financial filing in 2025.

Over the last 10 years, Prothena's book value per share changed from 11.44 in 2015 to 5.21 in 2025, a change of -54.5%.


Related Companies

Financial statements for NASDAQ:PRTA last updated on 7/2/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
Trump's gold order: the announcement they won't put on the front page
On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...
Reagan Gold Group | Sponsoredtc pixel
My next big call (under $1)
17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...
Crypto 101 Media | Sponsoredtc pixel
Trump’s $250 Bill – See Immediately
Former Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...
Stansberry Research | Sponsoredtc pixel
Ex-CIA Insider: “Prepare for a Mid-Term Meltdown”
Former CIA and Pentagon advisor Jim Rickards - who correctly called the 2008 recession, Trump's 2016 election,...
Paradigm Press | Sponsoredtc pixel
This same-day trade is getting a lot of attention
Zero-days-to-expiration trades happen every single day - and most traders either ignore them or use them wrong...
Base Camp Trading | Sponsoredtc pixel
Print this and keep it by your screen
Ever been right about a stock's direction and still lost money on the trade? It's almost never bad luck - it's...
Profits Run | Sponsoredtc pixel
Where to Put $100 Before Trump's New Tech Law Rolls Out
The Financial Times says a new tech law puts America 'on the verge of a financial revolution.' Yahoo Finance e...
Brownstone Research | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel